DNLC2A基因在卵巢恶性肿瘤组织中的表达及临床意义

Expression of DNLC2A mRNA in malignant ovarian tumours and its clinical significance

目的 :研究DNLC2A基因在人卵巢恶性肿瘤组织中的表达及其与卵巢恶性肿瘤临床病理特征的关系。方法 :采用半定量逆转录 聚合酶链反应 (RT PCR)法检测 4 2例卵巢恶性肿瘤组织和 4 2例正常卵巢组织中DNLC2AmRNA的表达。结果 :DNLC2AmR NA在卵巢恶性肿瘤组织中的表达显著高于正常卵巢组织 (P <0 .0 5 ) ,在晚期恶性卵巢肿瘤中的表达显著高于早期者 (P <0 .0 5 ) ,但在各组织类型中的表达无显著性差异 (P >0 .0 5 ) ,且与肿瘤细胞分化程度无关 (P >0 .0 5 )。结论 :DNLC2A基因的变异参与了卵巢癌的发病机制 。

Objective:To investigate the expression of DNLC2A mRNA in human malignant ovarian tumours and its relationship with clinicopathological characteristics.Method:The expression of DNLC2A mRNA in 42 cases of malignant ovarian tumours and 42 cases of normal ovary tissues was detected by semi quantity reverse transcription polymerase chain reaction (RT PCR).Results:The expression of DNLC2A mRNA in malignant ovarian tumours was significantly higher than that in normal ovary tissues (P<0.05).The expression of DNLC2A mRNA in late stage malignant ovarian tumours was higher than that in early stage(P<0.05),but unrelated to the pathological type or grade of tumors.Conclusion:The abnormal expression of DNLC2A gene might be involved in the carcinogenesis of malignant ovarian tumour and play additional roles in late stage of malignant ovarian tumours.